The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy | Zendy

Sandro Feriozzi | Zendy; Joan Torrás | Zendy; Markus Cybulla | Zendy; Kathy Nicholls | Zendy; Gere SunderPlassmann | Zendy; Michael L. West | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy

Author(s) -

Sandro Feriozzi,

Joan Torrás,

Markus Cybulla,

Kathy Nicholls,

Gere SunderPlassmann,

Michael L. West

Publication year - 2012

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.03130411

Subject(s) - medicine , fabry disease , renal function , enzyme replacement therapy , proteinuria , urology , creatinine , nephropathy , excretion , kidney disease , renal replacement therapy , endocrinology , gastroenterology , kidney , disease , diabetes mellitus

Fabry disease is a rare X-linked disease with multisystemic manifestations. This study investigated the effectiveness of long-term enzyme replacement therapy with agalsidase alfa in Fabry nephropathy treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research